Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

CAAT News & Views

CAAT News & Views ATLA 39, 511–513, 2011 511 sensitisation, toxicokinetics, carcinogenicity, CAAT Receives $1.2 Million FDA Grant and reproductive and repeated-dose toxicity. Four to five respondents per article, and an The FDA has awarded CAAT’s Director, Thomas extensive discussion with all the participants, Hartung, and his research team a grant to study led to agreement on all the items. The papers, the identification of pathways of developmental which will be published in ALTEX 1/2012, set neurotoxicity for high-throughput testing by priorities for test/model optimisation, valida- metabolomics. tion and integrated testing strategies, and pro- There is a critical concern that exposure to vide a link to Toxicology in the 21st Century, drugs and chemicals during early life con- with its pathway-based approaches. tributes to the increasing incidence of neurode- A two-day event will be held in March 2012, velopmental disorders in children, such as in Brussels, to present and discuss these lowered IQ, learning disabilities, autism, and papers. The meeting will be jointly hosted by a attention deficit and hyperactivity disorder number of stakeholder organisations, includ- (ADHD). The developing brain is more suscepti- ing: ASCCT, CAAT, COACH/SEURAT-1, DZF, ble to substance-induced injury than the adult ECOPA, ESTIV, HSI, IIVS, IVTIP and ToxCast. brain, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Alternatives to Laboratory Animals SAGE

CAAT News & Views

Alternatives to Laboratory Animals , Volume 39 (6): 3 – Dec 1, 2011
Download PDF
3 pages

Loading next page...
 
/lp/sage/caat-news-views-uc0i87mWRc

References (16)

Publisher
SAGE
Copyright
© 2011 Fund for the Replacement of Animals in Medical Experiments
ISSN
0261-1929
eISSN
2632-3559
DOI
10.1177/026119291103900604
Publisher site
See Article on Publisher Site

Abstract

ATLA 39, 511–513, 2011 511 sensitisation, toxicokinetics, carcinogenicity, CAAT Receives $1.2 Million FDA Grant and reproductive and repeated-dose toxicity. Four to five respondents per article, and an The FDA has awarded CAAT’s Director, Thomas extensive discussion with all the participants, Hartung, and his research team a grant to study led to agreement on all the items. The papers, the identification of pathways of developmental which will be published in ALTEX 1/2012, set neurotoxicity for high-throughput testing by priorities for test/model optimisation, valida- metabolomics. tion and integrated testing strategies, and pro- There is a critical concern that exposure to vide a link to Toxicology in the 21st Century, drugs and chemicals during early life con- with its pathway-based approaches. tributes to the increasing incidence of neurode- A two-day event will be held in March 2012, velopmental disorders in children, such as in Brussels, to present and discuss these lowered IQ, learning disabilities, autism, and papers. The meeting will be jointly hosted by a attention deficit and hyperactivity disorder number of stakeholder organisations, includ- (ADHD). The developing brain is more suscepti- ing: ASCCT, CAAT, COACH/SEURAT-1, DZF, ble to substance-induced injury than the adult ECOPA, ESTIV, HSI, IIVS, IVTIP and ToxCast. brain,

Journal

Alternatives to Laboratory Animals – SAGE

Published: Dec 1, 2011

There are no references for this article.